GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for PB-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma
Ended Project Grant Awarded Last action
- Award ID
- R44CA254613
- Recipient
-
Viewpoint Molecular Targeting, Inc. UEI RDZCK3F6AU73
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,999,532
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Funding
-
- $2,999,649.00 Federal
- $999,883.00 Non-federal
- Place of performance
- Iowa, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $999,883 | $0 | |
| Amendment | $999,883 | $999,883 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Original award | $999,883 | $0 |
Quick answers
Who received award R44CA254613?
R44CA254613 was awarded to Viewpoint Molecular Targeting, Inc. by National Cancer Institute (National Institutes of Health) on September 7, 2020.
How much is award R44CA254613 worth?
$3,999,532 has been obligated on R44CA254613: $2,999,649 in federal funding and $999,883 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award